Method for treating an individual suffering from bladder cancer
A method for treating an individual suffering from bladder cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, dostarlimab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus . The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.
1. A method for reducing the likelihood of developing bladder cancer in an individual human being, comprising:
administering BGC intravesicaly to the individual;
providing in the gut of the individual a population of beneficial bacteria selected from the group consisting of Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Streptococcus , and F. prausnitzii bacteria;
administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual human being; and
administering to the individual human being an immune checkpoint inhibitor.
2. The method as set forth in claim 1 , further comprising reducing the number of bacteria in an individual prior to the step of providing beneficial bacteria to the individual.
3. The method as set forth in claim 2 , wherein the step of reducing the number of bacteria in an individual comprises one of administering an antibiotic and using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) to selectively killing a pathogenic bacteria within the individual.
4. The method as set forth in claim 1 , further comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1), selectively killing a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria qonorrhoeae; Acinetobacter baumannii ; and Campylobacter bacteria, and wherein the immune checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, dostarlimab, AMP-224, AMP-514, STI-A1110, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010, wherein using the CRISPR-Cas systems, said pathogenic bacteria are killed while sparing other commensal bacteria.
5. The method of claim 4 , wherein said beneficial bacteria are encapsulated to avoid contact with oxygen.
6. The method as set forth in claim 4 , wherein the CRISPR-Cas or Cpf1 system is used to cut a gene expressed by the pathogenic bacteria.
7. A method for treating an individual suffering from bladder cancer, comprising,
using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1), selectively killing pathogenic bacteria within the individual, and administering to the individual an immune checkpoint inhibitor that specifically binds to an immune checkpoint protein selected from the group consisting of CTLA4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, KIR, LAG3, TIM-3 and VISTA, wherein using said CRISPR-Cas system, said pathogenic bacteria are killed while sparing other commensal bacteria.
8. The method as set forth in claim 7 , wherein the immune checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, dostarlimab, pidilizumab, AMP-224, AMP-514, STI-A1110, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.
9. The method as set forth in claim 7 , wherein the CRISPR-Cas or Cpf1 system is used to insert genes that have controllable elements such that the pathogenic bacteria cells are killed by triggering the expression of said inserted genes.
10. The method as set forth in claim 7 , wherein said pathogenic bacteria are selected from the group consisting of: Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis;
Enterococcus; E coli; Clostridium; Neisseria gonorrhoeae; Acinetobacter baumannii; and Campylobacter.
11. The method as set forth in claim 7 , wherein CRISPR-Cas or Cpf1 is used to facilitate RNA-guided site-specific DNA cleavage to kill the pathogenic bacteria.
12. The method of claim 7 , further comprising enhancing the growth of a beneficial bacteria in the individual selected from the group consisting of Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, F. prausnitzii and Streptococcus bacteria.
13. A method for treating an individual suffering from bladder cancer, comprising, providing in the bladder of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species; administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual human being; increasing the levels of at least one of Faecalibacterium prausnitzii, Bifidobacterium, Lachnospira, Veillonella, Coprococcus, Akkermansia muciniphila and Rothia in the individual's gut microbiome, administering to the individual an immune checkpoint inhibitor, and, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1(Cpf1) system, reducing the population of a second bacteria in the individual, said second bacteria selected from the group consisting of Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; Escherichia coli; Clostridium; Neisseria gonorrhoeae; Acinetobacter baumannii ; and Campylobacter , wherein using CRISPR-Cas systems, said pathogenic bacteria are killed while sparing other commensal bacteria.
14. The method as set forth in claim 13 , wherein the immune checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, dostarlimab, AMP-224, AMP-514, STI-A1110, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.
15. The method as set forth in claim 13 , wherein the CRISPR-Cas or Cpf1 system is used to cut a gene expressed by the second bacteria.
16. The method as set forth in claim 13 , wherein the CRISPR Cas system comprises one of Cas3 or Cas9.
17. The method as set forth in claim 13 , wherein the CRISPR Cas system is delivered using a bacteriophage.
18. The method as set forth in claim 13 , wherein the CRISPR Cas system comprises Cas3.
19. The method as set forth in claim 13 , wherein the CRISPR Cas system comprises Cas3 and is delivered using a bacteriophage.
20. The method as set forth in claim 13 , wherein using one of the CRISPR-Cas or Cpf1 system, said pathogenic bacteria are modified to reduce virulence factors of said pathogenic bacteria.